Bharat Bajantri, MD
Pulmonary Disease · Fort Wayne, INNPI 1043567886
Payments from drug & device makers
What this record shows
The money is spread across several categories — education (43.8%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 23 manufacturers reported payments, led by Intuitive Surgical at 57.7% of the total. Reporting peaked in 2023 at $4,692 and has fallen 91.4% since, to $403 in 2025.
Across 81 payments — averaging $90.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- Pinnacle Biologics, Inc$908
- Mallinckrodt Hospital Products Inc.$392
- AstraZeneca$348
- Regeneron Healthcare Solutions, Inc.$184
- Takeda Pharmaceuticals U.S.A., Inc.$183
- plus $1K from 17 others
Across 1 payment — averaging $21,661 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$22K
What the payments were for
- Travel & lodging$1,76924%
- Food & beverage$2,32932%
- Education$3,20044%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 8 | $4,208 |
| Pinnacle Biologics, Inc | 9 | $908 |
| Mallinckrodt Hospital Products Inc. | 6 | $392 |
| AstraZeneca | 17 | $348 |
| Regeneron Healthcare Solutions, Inc. | 4 | $184 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $183 |
| Johnson & Johnson | 3 | $178 |
| Boehringer Ingelheim | 4 | $159 |
| Actelion Pharmaceuticals US, Inc. | 2 | $154 |
| United Therapeutics Corporation | 3 | $147 |
| Abiomed | 2 | $69 |
| GSK | 4 | $59 |
| Olympus America Inc. | 1 | $50 |
| Philips North America LLC | 2 | $37 |
| Insmed, Inc. | 2 | $35 |
| Baxter Healthcare | 1 | $35 |
| Sanofi | 2 | $34 |
| Inogen, Inc. | 2 | $29 |
| Merck | 1 | $23 |
| Electromed, Inc. | 2 | $20 |
| Verona Pharma, Inc. | 1 | $18 |
| Viatris Specialty LLC | 1 | $15 |
| Amgen | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ION$3,000
- Da Vinci Surgical System$1,051
- Photofrin$569
- UPTRAVI$132
- OPSUMIT$132
- Monarch Platform$130
- DUPIXENT$122
- GLASSIA$122
- ACTHAR$121
- TEZSPIRE$102
How this compares
$7,298 in reported general payments places this provider in the 70th percentile of 258 pulmonary disease providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 129 | $117,453 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 115 | $80,745 |
| Breo ElliptaFluticasone/Vilanterol | 132 | $66,141 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 69 | $45,130 |
| Spiriva RespimatTiotropium Bromide | 34 | $24,064 |
| EliquisApixaban | 17 | $12,666 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $9,208 |
| Fluticasone-VilanterolFluticasone/Vilanterol | 14 | $4,436 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 25 | $4,068 |
| Arnuity ElliptaFluticasone Furoate | 17 | $3,261 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 143 | $3,170 |
| Montelukast Sodium | 94 | $680 |
| Roflumilast | 11 | $341 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 23 | $231 |
| Esomeprazole Magnesium | 11 | $209 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta | $59 | $267,599393 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $159 | $69,193103 claims |
| AstraZenecaBreztri Aerosphere | $348 | $9,20814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 258 pulmonary disease providers in Indiana.
Other pulmonary disease in Fort Wayne
- Daria LeeFort Wayne$69K
- Abhishek BiswasFort Wayne$30K
- Vatche IsrabianFort Wayne$22K
- Shivu KaushikFort Wayne$10K
- Vicente RodriguezFort Wayne$10K
- Manuel MartinezFort Wayne$9K
- Eric PetersonFort Wayne$9K
- David MaresAnderson$1.3M
- David WilsonSeymour$689K
- Giovanni InfusinoCrown Point$526K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.